Le Lézard11h
Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors
Exelixis, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved CABOMETYX® (cabozantinib) for the treatment of 1) adult and pediatric patients 12 years of age and older ...
Le Lézard11h
Keypoint Intelligence's Jeff Wettersten to Lead Packaging Innovation Session at FuturePrint TECH
Jeff Wettersten, VP of Packaging at Keypoint Intelligence, will take the stage at FuturePrint TECH's Packaging Day on April 3 with a compelling session titled "Transforming the 'Corrugated and Folding ...